Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with relapse d...

Descripción completa

Detalles Bibliográficos
Autores principales: Blancas, I., Olier, C., Conde, V., Bayo, J. L., Herrero, C., Zarcos-Pedrinaci, I., Carabantes, F., Baena-Cañada, J. M., Cruz, J., Ruiz-Borrego, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895931/
https://www.ncbi.nlm.nih.gov/pubmed/33608590
http://dx.doi.org/10.1038/s41598-021-83622-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895931/
https://www.ncbi.nlm.nih.gov/pubmed/33608590
http://dx.doi.org/10.1038/s41598-021-83622-1

Ejemplares similares